Trial Profile
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Tinostamustine (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mundipharma EDO; Mundipharma GmbH
- 24 Oct 2023 Results assessing safety and efficacy in a subset of patients (n=49) with soft tissue sarcoma presented at the 48th European Society for Medical Oncology Congress.
- 20 Sep 2023 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Results (n=36) presented at the 59th Annual Meeting of the American Society of Clinical Oncology